The study find that the potential treatment of liver disease, according to a study by Temple University, therefore the Geisinger Obesity Institute and the Translational Genomics Research Institute (TGen), an affiliate of City of Hope. Because The findings are detailed in a study published in the scientific journal PLoS One. But The study results suggest that increased expression of AEBP1 correlates with the severity of liver fibrosis in patients with NASH (nonalcoholic steatohepatitis), which is a type of NAFLD (nonalcoholic fatty liver disease), the most common cause of liver damage.
Treatment of liver disease
NASH indicates there is both inflammation and liver cell damage, along with fat in the liver. “Given the strong link between fibrosis and risk of liver-related mortality; efforts to identify and characterize the specific mechanisms contributing to NAFLD progression are critical for the development of effective therapeutic and preventative strategies;” said Dr. Johanna DiStefano, head of the Diabetes and Fibrotic Disease Unit at TGen.
One of the study’s major findings is that AEBP1 regulates the expression of a network of at least nine genes related to fibrosis: AKR1B10, CCDC80, DPT, EFEMP1; ITGBL1, LAMC3, MOXD1, SPP1, and STMN2. “These findings indicate that AEBP1 may be a central regulator of a complex fibrosis gene expression network in the human liver;” said Dr. DiStefano, the study’s senior author. The liver is a vital organ present in vertebrates and some other animals; it has a wide range of functions; but a few of which are detoxification, protein synthesis; and production of biochemicals necessary for digestion.
The liver is necessary for survival; there is currently no way to compensate for the absence of liver function. This organ plays a major role in metabolism and has a number of functions in the body; therefore including glycogen storage, decomposition of red blood cells, plasma protein synthesis, hormone production; and detoxification. Because It lies below the diaphragm in the thoracic region of the abdomen. It produces bile, an alkaline compound which aids in digestion; via the emulsification of lipids.
It also performs and regulates a wide variety of high-volume biochemical reactions requiring highly specialized tissues, including the synthesis and breakdown of small and complex molecules; but many of which are necessary for normal vital functions. Therefore “Our work shows that AEBP1 parallels the onset and severity of fibrosis in NASH patients, and suggest that AEBP1 may represent a specific therapeutic target to prevent the development of NASH fibrosis,” said Dr. Glenn S. Gerhard, Chair of the Department of Medical Genetics and Molecular Biochemistry at the Lewis Katz School of Medicine at Temple University. Dr. Gerhard is the study’s lead author.